Compare Amphastar Pharmaceuticals Inc (AMPH) vs KeyCorp (KEY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs KeyCorp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.44 (market cap $863.95M), while KeyCorp trades at $22.72 (market cap $24.31B). The key difference: KeyCorp is far larger — about 28.1× Amphastar Pharmaceuticals Inc's market cap, and KeyCorp pays a 3.62% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | KEY | |
|---|---|---|
Market Cap | $863.95M | $24.31B |
Sector | Health | Financials |
52-Week High | $30.81 | $23.99 |
52-Week Low | $16.87 | $16.78 |
Enterprise Value | $1.26B | — |
Dividend Yield | — | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
KeyCorp (KEY) trades at $22.73, up 0.31% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.41. Recent Q2 2026 earnings beat estimates with EPS of $0.44, driven by net interest income growth and fee expansion. The acquisition of Clearwater UK bolsters its investment banking presence, while a 3.6% dividend yield adds income appeal.
Outlook is positive with earnings momentum and strategic acquisitions supporting growth, but risks include interest rate sensitivity and competitive pressures. Wall Street sentiment is bullish with 61% buy ratings, though net cash flow volatility and modest ROE of 2.72% warrant caution for value-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
